#1 Clinical Trials Search in Europe

Find a Clinical Trial

Search Trials by Disease

Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
Rare Diseases Treatments

Search Trials by Disease

Neurodermatitis Pyruvate dehydrogenase complex deficiency Spinal cord injury Anaemia Acute myeloid leukaemia refractory Hypophosphatasia Stress cardiomyopathy Acute on chronic liver failure Autoimmune myositis Cystic fibrosis gastrointestinal disease Astrocytoma malignant Antisynthetase syndrome Spinal cord injury cervical Vulval cancer recurrent Restless legs syndrome More trials…

Learn about Rare Diseases

Antisynthetase syndrome – Basic Information Waldenstrom’s macroglobulinaemia refractory – Diagnostics Hairy cell leukaemia recurrent – Diagnostics Hereditary optic atrophy – Treatment Atypical haemolytic uraemic syndrome – Life with Disease Pleomorphic leiomyosarcoma – Trials in Disease Systemic mastocytosis – Diagnostics Advanced systemic mastocytosis – Life with Disease Medulloblastoma recurrent Osteosarcoma recurrent – Trials in Disease More diseases
Vaccine Clinical Trials
Pediatric Clinical Trials
Resources for Patients

Browse Innovative Treatments

Isotretinoin LY3537021 [18F]-Altanserin Glucose, Anhydrous Pyridoxine ZOREVUNERSEN SODIUM Cefalexin LY3841136 SODIUM VIPOGLANSTAT Rapcabtagene Autoleucel Fluasterone Zoledronic Acid Monohydrate Inaxaplin Letetresgene Autoleucel Progesterone, Micronised Nacystelyn TORASEMIDE Camizestrant Doxycycline Hyclate Mva-209-Fsp-B3 More therapies…

Learn about Your Condition

PIK3CA-activated mutation Andersen-Tawil syndrome Vertigo Mucopolysaccharidosis I Stem cell transplant CADASIL Cervical dysplasia Vitiligo Mucopolysaccharidosis II Immune-mediated myositis Hereditary angioedema Post cardiac arrest syndrome Primary biliary cholangitis Anal cancer metastatic Hepatobiliary cancer More diseases
Healthy Volunteers
Patient Guide
Our Partners
About Us
Contact us
Region

🇪🇺 Europe

🇦🇹 Austria

🇭🇷 Croatia

🇨🇿 Czech Republic

🇩🇰 Denmark

🇪🇪 Estonia

🇫🇮 Finland

🇫🇷 France

🇩🇪 Germany

🇮🇸 Iceland

🇮🇹 Italy

🇱🇻 Latvia

🇱🇹 Lithuania

🇳🇱 Netherlands

🇳🇴 Norway

🇵🇱 Poland

🇵🇹 Portugal

🇷🇴 Romania

🇸🇰 Slovakia

🇸🇮 Slovenia

🇪🇸 Spain

🇸🇪 Sweden

Plasma cell myeloma refractory

Study of isatuximab and pegenzileukin combination treatment for patients with relapsed or refractory multiple myeloma who previously received anti-CD38 and anti-BCMA therapy

Not recruiting

1 1 1
Investigated Diseases:
- Plasma cell myeloma refractory
Investigated Drugs:
- Pegenzileukin
- Isatuximab
Study of isatuximab, belantamab mafodotin and dexamethasone combination for patients with relapsed or refractory multiple myeloma

Not recruiting

1 1 1 1
Investigated Diseases:
- Plasma cell myeloma refractory
Investigated Drugs:
Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Not recruiting

2 1 1 1
Investigated Drugs:
+4

1 … 5 6 7

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

Plasma cell myeloma refractory

Study of isatuximab and pegenzileukin combination treatment for patients with relapsed or refractory multiple myeloma who previously received anti-CD38 and anti-BCMA therapy

Study of isatuximab, belantamab mafodotin and dexamethasone combination for patients with relapsed or refractory multiple myeloma

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Investigational Drugs in This Location

Medical Conditions Being Studied in This Location

We use cookies